Can increasing the dose of Exelon (rivastigmine) cause jerky movements?

Increasing Exelon Dose and Jerky Movements

While jerky movements (tremor) are not listed as a primary adverse effect of Exelon (rivastigmine) in FDA labeling, clinical evidence demonstrates that dose increases can cause or worsen tremor, particularly during titration phases. 1

Understanding the Risk

The FDA label for Exelon specifically warns about extrapyramidal symptoms, noting that "like other cholinomimetics, rivastigmine may exacerbate or induce extrapyramidal symptoms" and that "worsening of parkinsonian symptoms, particularly tremor, has been observed in patients with dementia associated with Parkinson's disease." 1

Clinical Evidence on Tremor

Research in patients with Parkinson's disease dementia provides the clearest picture:

• In a 24-week controlled trial, tremor as an adverse event occurred in 10.2% of rivastigmine-treated patients versus 3.9% on placebo (p=0.012) 2
• Tremor was most frequently reported during the titration phase of treatment 2
• The effect appears to be transient - in patients who continued into an open-label extension, only 3.8% of those already on rivastigmine reported tremor, compared to 12.2% of those newly starting the drug 2
• A smaller study showed tremor scores increased by an average of 0.4 points, with 27% of patients experiencing worsening tremor (increase of 1-5 points) 3

Important Caveats

The tremor is typically mild and transient:

• Only 1.7% of patients discontinued due to tremor in controlled trials 2
• No dose-dependent relationship was clearly established 2
• Long-term motor outcomes showed no evidence of progressive worsening 2
• Improvements in cognitive function and activities of daily living occurred regardless of whether tremor was reported 2

Clinical Management Algorithm

When increasing Exelon dose:

1. Warn patients/caregivers that temporary worsening of tremor or jerky movements may occur during dose escalation
2. Titrate slowly - increase by 1.5 mg twice daily (oral) or 4.6 mg/24h increments (patch) no more frequently than every 4 weeks 4
3. Monitor most closely during the first 4-8 weeks after each dose increase
4. If tremor develops:
   • Assess severity and functional impact
   • Consider holding at current dose for additional 2-4 weeks before further titration
   • Only discontinue if tremor is severe or functionally limiting
   • Remember that tremor typically improves with continued treatment at the same dose

Do not confuse this with the primary gastrointestinal adverse effects (nausea, vomiting, diarrhea) which are the main dose-limiting toxicities and occur in 6-23% of patients depending on formulation and dose 1.